Carl L. Gordon, Ph.D., CFA
Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was at Fellow at The Rockefeller University from 1993 to 1995. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.
Jonathan T. Silverstein, J.D.
Jonathan T. Silverstein, J.D., is a Partner and a Co-Head of Global Private Equity at OrbiMed. Mr. Silverstein joined OrbiMed in 1999 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a Director of Life Sciences in the Investment Banking Department at Sumitomo Bank. For the last four years (2012 to 2015) Forbes® Magazine named Mr. Silverstein one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List". Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.
Michael B. Sheffery, Ph.D
Michael B. Sheffery, Ph.D., is a Partner Emeritus with OrbiMed. Dr. Sheffery was formerly Head of the Laboratory of Gene Structure and Expression at Memorial Sloan-Kettering Cancer Center. He received both his Ph.D. in Molecular Biology and his B.A. in Biology from Princeton University. Dr. Sheffery joined Mehta and Isaly in 1996 as a Senior Analyst covering the biotechnology industry.
Rishi Gupta, J.D.
Private Equity Partner
Rishi Gupta, J.D., is a Private Equity Partner. Previously, he was a healthcare investment banker at Raymond James & Associates, served as Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. He received his A.B. degree magna cum laude in Biochemical Sciences from Harvard College and holds a J.D. from the Yale Law School.
David Bonita, M.D.
Private Equity Partner
David Bonita, M.D., is a Private Equity Partner. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Chau Q. Khuong
Private Equity Partner
Chau Q. Khuong is a Private Equity Partner. He joined OrbiMed in 2003. Mr. Khuong has experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer Associate in the New Ventures technology transfer group at Columbia University. Mr. Khuong holds a B.S. in molecular, cellular and developmental biology with a concentration in biotechnology and an M.P.H. with a concentration in infectious disease, both from Yale University.
Peter Thompson, M.D.
Private Equity Partner
Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Cleave BioSciences, is an executive of Chiron Corporation and Becton Dickinson and serves as a Director on several public and private company Boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.
Mona Ashiya, Ph.D.
Mona Ashiya, Ph.D., is a Principal on the Private Equity team. Before joining OrbiMed, she covered the biotechnology industry as a member of J.P. Morgan's biotechnology equity research team. Her previous professional experience includes positions at Needham & Co., the Global Alliance for TB Drug Development, and the Harvard Business School. She has also published scientific articles in various peer reviewed journals. She earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute where her research focused on mechanisms of programmed cell death.
Imran Babar, Ph.D.
Imran A. Babar, Ph.D., is a Senior Associate on the Private Equity team. Prior to joining OrbiMed, Dr. Babar was a Biotechnology Associate at Cowen & Company, where he covered 20+ companies in the therapeutics space. He also serves as the V.P. of Scientific Affairs for Rare Genomics Institute, a nonprofit biotech focused on helping rare disease patients. Dr. Babar completed his Ph.D. in molecular biology at Yale University, where he researched microRNAs as both causes and treatments for cancers. While at Yale, he was a Howard Hughes Fellow, Harvey Fellow, and a fellow for the Lindau Nobel Laureate Meeting for young scholars. Prior to Yale, he completed his B.A. in Biology at Carleton College and conducted research at M.I.T. and N.I.H.
Badreddin Edris, Ph.D.
Badreddin Edris, Ph.D., is a Senior Associate on the Private Equity team. Prior to joining OrbiMed, he was a Consultant at Bain & Company, where he advised clients in the biotechnology and pharmaceutical industries on a range of strategic initiatives spanning research, clinical development, commercial planning, operations, portfolio management, and business development. He also has prior experience at Genentech and Mission Bay Capital. Dr. Edris received his B.I.S. in Microbiology from Weber State University, his M.S. in Biology from Stanford University, and his Ph.D. in Genetics from Stanford University School of Medicine. While at Stanford, he was an N.S.F. Graduate Research Fellow, and his work on novel therapeutic targets in soft-tissue cancers has been published in several peer-reviewed journals.
Daniel O'Connell, M.D., Ph.D.
Daniel O'Connell, M.D., Ph.D., is an Associate on the Private Equity team. Before joining OrbiMed, Dr. O'Connell was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals. In this role, he headed projects developing small molecules to raise HDL-cholesterol, culminating with an FDA filing of a novel compound in 2010. He has authored articles in peer-reviewed journals describing the design and synthesis of novel enzyme inhibitors and the effects of niacin in animal models of dyslipidemia. Dr. O'Connell received his M.D. and his Ph.D. in biochemistry at Tufts University School of Medicine. He holds SB degrees from M.I.T. in both chemistry and mathematics.
Diyong Xu is an Associate on the Private Equity team. Prior to joining OrbiMed, Mr. Xu was an investment banking analyst in the healthcare group at Lazard where he focused on M&A, financing and strategic advisory for biotech, diagnostics and pharma clients in U.S., Japan and E.U. Mr. Xu earned his M.S. degree in Management Science and Engineering from Stanford University and M.S. degree in Molecular and Cellular Biology from Dartmouth Medical School. He holds a B.S. degree in Biology from Zhejiang University in China.
Gaurav Gupta, M.D.
Gaurav Gupta, M.D., is an Associate on the Private Equity team. Prior to joining OrbiMed, Dr. Gupta served as a resident in neurological surgery at Columbia University Medical Center for three years, where he also completed post-doctoral research at the Institute for Cancer Genomics. Intellectual property derived from his graduate school research into mechanisms of atherogenesis was licensed to the startup company Arginetix Inc., which was acquired by Astra Zeneca. He has co-authored over a dozen articles in peer-reviewed journals, filed a patent on a device for use in spine surgery, and edited a book on tissue engineering. Dr. Gupta obtained his M.D. from the Stanford University School of Medicine where he was a recipient of the Paul and Daisy Soros Fellowship, and his B.S. and M.S. in Biomedical Engineering from Johns Hopkins University, where he was a Charles R. Westgate Scholar.
Jessica White is an Analyst on the Private Equity team. Prior to joining OrbiMed, Ms. White was an investment banking analyst in the healthcare group at Bank of America Merrill Lynch where she focused on M&A, financing and strategic advisory for global life sciences, medical technologies and healthcare services clients. Ms. White holds a B.A. in Molecular Biology and Economics from the University of Pennsylvania
Collin Todd is an Analyst on the Private Equity team. Prior to joining OrbiMed, Mr. Todd was an investment banking analyst in the healthcare group at Bank of America Merrill Lynch where he focused on M&A, financing, and strategic advisory for biotech and pharma clients in the US and EU. Mr. Todd holds a B.A. in Economics from the University of California, Los Angeles.